Sierra Oncology Reports First Quarter 2019 Results

Wednesday, May 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

SIERRA ONCOLOGY, INC. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data)

Three Months EndedMarch 31,

2019

2018

Operating expenses:

Research and development

$

10,137

$

8,334

General and administrative

3,365

3,420

Total operating expenses

13,502

11,754

Loss from operations

(13,502)

(11,754)

Other income, net

325

272

Loss before provision for (benefit from) income taxes, net

(13,177)

(11,482)

Provision for (benefit from) income taxes, net

(145)

43

Net loss

$

(13,032)

$

(11,525)

Net loss per common share, basic and diluted

$

(0.17)

$

(0.19)

Weighted-average shares used in computing net loss per share, basic and diluted

 

74,485,295

 

59,722,743



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store